Urogen Pharma Stock Investor Sentiment
| URGN Stock | USD 14.24 0.25 1.73% |
About 66% of UroGen Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding UroGen Pharma suggests that many traders are alarmed. UroGen Pharma's investor sentiment overview provides quick insight into current market opportunities from investing in UroGen Pharma. The current market sentiment, together with UroGen Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use UroGen Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
UroGen Pharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of UroGen daily returns and investor perception about the current price of UroGen Pharma as well as its diversification or hedging effects on your existing portfolios.
UroGen |
UroGen Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards UroGen Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about UroGen Pharma that are available to investors today. That information is available publicly through UroGen media outlets and privately through word of mouth or via UroGen internal channels. However, regardless of the origin, that massive amount of UroGen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of UroGen Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of UroGen Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to UroGen Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive UroGen Pharma alpha.
UroGen Pharma Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | Exercise or conversion by Schoenberg Mark of 2000 shares of UroGen Pharma subject to Rule 16b-3 | 02/02/2024 |
2 | Sale by Schoenberg Mark of 1137 shares of UroGen Pharma | 02/05/2024 |
3 | This Insider Has Just Sold Shares In UroGen Pharma | 02/08/2024 |
4 | UroGen Pharma Ltd Reports Solid JELMYTO Growth Amidst Financial Challenges | 03/14/2024 |
5 | UroGen Pharma NASDAQURGN shareholders incur further losses as stock declines 21 percent this week, taking five-year losses to 61 | 03/15/2024 |
6 | UroGen Pharma Ltds Chief Medical Officer Mark Schoenberg Sells 12,000 Shares | 03/20/2024 |
7 | Urogen sues Teva over Jelmyto patents | 04/03/2024 |
8 | UroGen Pharma Ltd. Stake Lifted by China Universal Asset Management Co. Ltd. - Defense World | 04/08/2024 |
9 | UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Ri... | 04/15/2024 |
10 | UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelia... | 04/17/2024 |
Check out UroGen Pharma Hype Analysis, UroGen Pharma Correlation and UroGen Pharma Performance. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for UroGen Stock analysis
When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.55) | Revenue Per Share 2.869 | Quarterly Revenue Growth 0.301 | Return On Assets (0.26) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.